.beta. APP-C100 receptor
AssigneesBristol-Myers Squibb Company, The McLean Hospital Corporation
InventorsSusan P. Manly, Michael R. Kozlowski, Rachael L. Neve
Life of this patent
Estimating the term…
Abstract
The present invention relates to the cloning of .beta.APP-C100 receptor (C100-R), and genetically engineered host cells which express the C100-R. Such engineered cells may be used to evaluate and screen drugs and analogs of .beta.-APP involved in Alzheimer's Disease.
Claims7
An isolated and purified C100R free of other mammalian proteins comprising the amino acid sequence of SEQ ID NO:
- 2.
An isolated and purified naturally occurring mammalian C100R, free from other mammalian proteins, that is encoded by a nucleotide sequence that hybridizes under high stringency conditions to the nucleic acid of SEQ ID NO:
- 1 and binds to the .beta.APP-C100 peptide.
A fusion protein comprising a naturally occurring mammalian C100-R, that is encoded by a nucleic acid sequence that hybridizes under high stringency conditions to the nucleic acid of SEQ ID NO:
- 1 and binds to the .beta.APP-C100 peptide, linked to a heterologous polypeptide.
An isolated and purified protein free from other mammalian proteins containing a C100-R serine/threonine kinase conserved catalytic core sequence comprising the following amino acids:
- VIHRDIXSDNILL (amino acids 304-316 of SEQ ID NO.2).
An isolated and purified C100-R peptide free from other mammalian proteins containing a C100-R serine/threonine kinase conserved catalytic core sequence comprising the following amino acids:
- VIHRDIKSNILL (amino acids 304-316 of SEQ ID NO. 2).
A fusion protein comprising a C100-R comprising the amino acid sequence of SEQ ID NO:2 linked to a heterologous polypeptide.
A fusion protein comprising a isolated C100-R polypeptide comprising the following amino acids:
- VIHRDIKSDNILL (amino acids 304-316 of SEQ ID No. 2), linked to a heterologous polypeptide.
Dependencies are inferred from the claim text.